Medline (MDLN Quick QuoteMDLN - Free Report) reported $7.86 billion in revenue for the quarter ended September 2026, representing no change year over year. EPS of $0.44 for the same period compares to $0 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $7.69 billion, representing a surprise of +2.18%. The company delivered an EPS surprise of +29.41%, with the consensus EPS estimate being $0.34.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Medline performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales to external customers- Supply Chain Solutions: $4.22 billion versus the four-analyst average estimate of $4.05 billion.
• Net sales to external customers- Medline Brand: $3.64 billion versus $3.64 billion estimated by four analysts on average.
• Adjusted EBITDA- Medline Brand: $943 million versus the three-analyst average estimate of $852.45 million.
• Adjusted EBITDA- Corporate & Other: $-167 million compared to the $-204.43 million average estimate based on three analysts.
• Adjusted EBITDA- Supply Chain Solutions: $184 million versus $202.69 million estimated by three analysts on average.

View all Key Company Metrics for Medline here>>>

Shares of Medline have returned -4.1% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.